Sava Infond d.o.o. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sava Infond d.o.o. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 690 shares of the biopharmaceutical company’s stock, valued at approximately $492,000.

Other large investors have also recently made changes to their positions in the company. Larson Financial Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 127.3% during the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 28 shares during the period. Independent Advisor Alliance acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $231,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $39,000. D.A. Davidson & CO. grew its position in Regeneron Pharmaceuticals by 5.1% in the 3rd quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company’s stock valued at $863,000 after acquiring an additional 40 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth about $151,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $635.83 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $69.51 billion, a P/E ratio of 16.61, a PEG ratio of 2.34 and a beta of 0.27. The business has a 50 day simple moving average of $684.76 and a 200-day simple moving average of $803.87. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $11.86 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Finally, BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.